Research on GLP-1 Drugs
Peer-reviewed research on semaglutide and tirzepatide — STEP trials, SURMOUNT-1, SELECT cardiovascular outcomes, post-discontinuation regain, and lean-mass loss.
8
Papers
6
Strong evidence
21–24
Years covered
Where this literature sits
GLP-1 receptor agonists (semaglutide, tirzepatide) are the most effective pharmacotherapy for weight loss in trial history — STEP 1 produced 14.9% mean weight loss at 68 weeks, and SURMOUNT-1 produced 20.9%. The cardiovascular benefit (SELECT 2023) is real: 20% reduction in major adverse events in obese non-diabetic adults. But the trial literature also names two underappreciated problems: (1) ~25–40% of total weight lost is lean mass — a sarcopenia and bone-density risk demanding active countermeasures (Linge 2024, Jensen 2024); (2) discontinuation produces rapid regain (STEP 1 extension: two-thirds of weight back at one year).
The honest position from the literature: these drugs work, work better with serious lifestyle scaffolding (resistance training + 1.6–2.0 g/kg protein + UPF reduction), and probably need to be lifelong for many users — or replaced by sustained behaviour at the off-ramp. Below: the pivotal trials and the muscle/bone literature.
Evidence mix on this topic
- Strong evidence6
- Moderate evidence2
Every paper behind the claim
Filter by grade or flip the order. Each card links straight to PubMed, the DOI or the journal — read the original rather than our summary of it.
- Moderate evidence2024
Body composition and cardiometabolic effects of GLP-1 receptor agonists: changes in lean mass
Linge J et al. · Obesity Reviews
Across GLP-1 trials, ~25–40% of total weight lost on semaglutide is lean mass — meaningful sarcopenia risk.
- Moderate evidence2024
Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment
Jensen SBK et al. · JAMA Network Open
GLP-1 monotherapy reduced bone mineral density at hip and spine; exercise prevented this loss.
- Strong evidence2023
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff AM et al. · New England Journal of Medicine
SELECT trial: semaglutide reduced major adverse cardiovascular events by 20% in obese non-diabetic adults.
- Strong evidence2022
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
Wilding JPH et al. · Diabetes, Obesity and Metabolism
One year after discontinuation, two-thirds of lost weight and most cardiometabolic improvements regained.
GLP-1 DrugsSource ↗ - Strong evidence2022
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
Jastreboff AM et al. · New England Journal of Medicine
SURMOUNT-1: tirzepatide produced 20.9% mean weight loss at the highest dose over 72 weeks.
GLP-1 DrugsSource ↗ - Strong evidence2022
Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)
Garvey WT et al. · Nature Medicine
STEP 5: 15.2% mean weight loss sustained at 104 weeks with continued semaglutide treatment.
GLP-1 DrugsSource ↗ - Strong evidence2021
Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
Wilding JPH et al. · New England Journal of Medicine
Pivotal STEP 1 trial: 14.9% mean body-weight reduction with semaglutide 2.4 mg over 68 weeks vs 2.4% placebo.
GLP-1 DrugsSource ↗ - Strong evidence2021
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)
Davies M et al. · The Lancet
STEP 2: 9.6% body-weight reduction with semaglutide 2.4 mg in T2D over 68 weeks vs 3.4% placebo.
Nothing metabolic sits on its own
Sleep moves insulin. Stress moves visceral fat. Protein moves total intake. The other shelves in the library are usually where the missing half of the answer lives.
- Ultra-Processed Food8 studies
- Metabolic Adaptation8 studies
- Insulin Resistance14 studies
- Fasting6 studies
- Seed Oils7 studies
- Ancestral Diet7 studies
- Sleep & Circadian9 studies
- Exercise & Strength15 studies
- Women-Specific9 studies
- Gut Microbiome8 studies
- Protein Leverage9 studies
- Heart Disease12 studies
- Glucose Variability7 studies
- Cortisol & Stress8 studies
GLP-1 Drugs
Reading this evidence honestly
Of the 8 papers filed under this topic, 6 carry a strong-evidence grade — replicated trials or large meta-analyses — and 0 sit in the contested or mechanism-only tiers where the human outcome has not been settled.
A mixed distribution is normal and honest. Topics where every paper is graded strong are usually topics where the inconvenient papers have been quietly left out.
6 of 8 papers
2 of 8 papers
Evidence grades describe the strength of the research, not a promise about your outcome.
Papers describe populations. Your labs describe you.
The free assessment takes the research above and asks which parts of it apply to your pattern — then names the protocol the evidence actually supports for it.
Educational only, not medical advice. Citing a study is not a recommendation to act on it. Consult your physician before major dietary changes or altering prescribed medication. These statements have not been evaluated by the Food and Drug Administration. Individual results vary; no outcome is guaranteed.